Next Article in Journal
Novel Purine Derivative ITH15004 Facilitates Exocytosis through a Mitochondrial Calcium-Mediated Mechanism
Next Article in Special Issue
Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation
Previous Article in Journal
Lipidomic Profile and Enzymes Activity in Hepatic Microsomes of Rats in Physiological and Pathological Conditions
 
 
Review

Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy

1
Somerville College, University of Oxford, Woodstock Road, Oxford OX2 6HD, UK
2
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Tzong-Shyuan Lee
Int. J. Mol. Sci. 2022, 23(1), 441; https://doi.org/10.3390/ijms23010441
Received: 30 November 2021 / Revised: 21 December 2021 / Accepted: 28 December 2021 / Published: 31 December 2021
Long-term cardiovascular complications of cancer therapy are becoming ever more prevalent due to increased numbers of cancer survivors. Cancer therapy-induced cardiotoxicity (CTIC) is an incompletely understood consequence of various chemotherapies, targeted anti-cancer agents and radiation therapy. It is typically detected clinically by a reduction in cardiac left ventricular ejection fraction, assessed by echocardiography. However, once cardiac functional decline is apparent, this indicates irreversible cardiac damage, highlighting a need for the development of diagnostics which can detect CTIC prior to the onset of functional decline. There is increasing evidence to suggest that pathological alterations to cardiac metabolism play a crucial role in the development of CTIC. This review discusses the metabolic alterations and mechanisms which occur in the development of CTIC, with a focus on doxorubicin, trastuzumab, imatinib, ponatinib, sunitinib and radiotherapy. Potential methods to diagnose and predict CTIC prior to functional cardiac decline in the clinic are evaluated, with a view to both biomarker and imaging-based approaches. Finally, the therapeutic potential of therapies which manipulate cardiac metabolism in the context of adjuvant cardioprotection against CTIC is examined. Together, an integrated view of the role of metabolism in pathogenesis, diagnosis and treatment is presented. View Full-Text
Keywords: cardiotoxicity; metabolism; chemotherapy; heart failure; cardioprotection cardiotoxicity; metabolism; chemotherapy; heart failure; cardioprotection
Show Figures

Figure 1

MDPI and ACS Style

Choksey, A.; Timm, K.N. Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. Int. J. Mol. Sci. 2022, 23, 441. https://doi.org/10.3390/ijms23010441

AMA Style

Choksey A, Timm KN. Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. International Journal of Molecular Sciences. 2022; 23(1):441. https://doi.org/10.3390/ijms23010441

Chicago/Turabian Style

Choksey, Anurag, and Kerstin N. Timm. 2022. "Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy" International Journal of Molecular Sciences 23, no. 1: 441. https://doi.org/10.3390/ijms23010441

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop